Thymosin Beta-4 (TB-500) is a peptide known for its ability to promote regeneration in the body. Studies in animals have demonstrated that the use of Thymosin Beta-4 can help to heal wounds in dermal, corneal, and cardiac cells, improve cell survival, promote blood vessel formation, and increase the maturation of stem cells. Thymosin Beta-4 has also been found to decrease levels of inflammatory cytokines and chemokines.
Research conducted on rats and mice demonstrated the efficacy of topical Thymosin Beta-4 in treating alkali and heptanol-related injuries to the eyes and skin. By administering 5 micrograms/5 microliters of Thymosin Beta-4 liquid eye drops twice per day, the corneal epithelium moved rapidly over the surface of the cornea to repair alkali injury. Thymosin Beta-4 alleviates inflammation by decreasing the levels of matrix metalloproteinases, activating nF kappa b, and blocking TNF cytokine release. Thymosin Beta-4 also increases the synthesis of laminin-5, which promotes cell contact and migration in the corneal epithelium and decreases apoptosis while increasing the rate of angiogenesis.
In another study, Thymosin Beta-4 was used to treat dermal wounds in rats and mice. Animals were treated with either a PBS form or a hydrogel of Thymosin Beta-4 in doses varying from 5 to 50 micrograms/50 microliters/wound. The application of Thymosin Beta-4 led to an increase in the rate of collagen deposition, keratinocyte migration, and angiogenesis. Studies conducted on rats and mice with various forms of impaired healing such as diabetes or advanced age reported that the use of Thymosin Beta-4 accelerated the healing process in the test subjects.
Thymosin Beta-4 has been shown to have positive effects in various animals when treating cardiovascular disease, nerve damage, septic shock, and dermal injury. For intracardiac injection of Thymosin Beta-4, the typical dose was 400 ng, while retro infusion doses ranged around 15 mg. In the coronary ligation models in mice, Thymosin Beta-4 promoted repair throughout the cardiac muscle. Additionally, in the refusion injury model of sheep, Thymosin Beta-4 prevented damage to the vascular system.
Thymosin Beta-4 helps to lower inflammation in the body and reduce levels of proinflammatory cytokines. In a study conducted by Phlip and Kleinman, endotoxins were injected into rats to examine the anti-inflammatory properties of Thymosin Beta-4. After dosing with Thymosin Beta-4, the lethality of endotoxin-induced septic shock was greatly reduced, as well as the inflammatory mediators found in association with septic shock. Reduced levels of Thymosin Beta-4 were found in rats with non-induced septic shock as well as when injected with the endotoxin, indicating that Thymosin Beta-4 can play an important role in treating sepsis.
According to this study, the administration of Thymosin Beta-4 resulted in a significant reduction in the lethality of endotoxin-induced septic shock and the associated inflammatory mediators. Interestingly, the levels of Thymosin Beta-4 were found to decrease naturally when sepsis was induced in rats. Lower levels of Thymosin Beta-4 were also observed in rats with non-induced septic shock or those injected with endotoxin, suggesting that Thymosin Beta-4 may play a crucial role in sepsis treatment.
Similar to its protective role in the cardiovascular system, Thymosin Beta-4 has demonstrated a protective effect on the nervous system both in vivo and in vitro. In rats, Thymosin Beta-4 was found to combat the loss of hippocampal neurons induced by kainic acid treatment when administered twice daily for 5 days.
In another study, treatment with Thymosin Beta-4 was shown to improve functionality, increase the amount of mature oligodendrocytes, and reduce inflammation in mice with autoimmune encephalomyelitis. Thymosin Beta-4 was also found to protect against glutamate-induced and ethanol toxicity in vitro.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Thymosin Beta-4 (TB-500) is a high-purity research peptide used to investigate cellular repair mechanisms, actin dynamics, and tissue regeneration pathways in controlled laboratory models. This 43–amino acid peptide is a fragment of the naturally occurring timbetasin protein and is widely utilized in preclinical research focused on wound healing, angiogenesis, and recovery following ischemic or mechanical injury.
Each vial of Thymosin Beta-4 is synthesized to rigorous research-grade specifications and verified by independent third-party analytical testing to confirm peptide identity and purity.
Thymosin Beta-4 Research Peptide Specifications:
| Unit Size | 5 or 10mg/vial |
| Unit Quantity | 1 vial |
| Purity (HPLC) | > 99% |
| Sequence | Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH |
| Molecular Formula | C212H350N56O78S |
| Molecular Weight | ≈ 4963.5 g/mol |
| CAS Number | 77591-33-4 |
| Appearance | Lyophilized White Powder |
| Source | Chemical Synthesis |
| Storage Conditions | Store lyophilized Thymosin Beta-4 at -20 °C in a dark, dry environment. After reconstitution, short-term storage at 2–8 °C is recommended for laboratory use. |
| Research Use Only | This Thymosin Beta-4 peptide is intended strictly for laboratory research applications. Not for human consumption, medical, or veterinary use. Please review all terms of service prior to ordering. |
Thymosin Beta-4 (Tβ4) is a naturally occurring actin-sequestering peptide that plays a central role in cell migration, cytoskeletal organization, and tissue remodeling. In preclinical research, it is frequently studied as a cytoprotective and pro-regenerative peptide with broad activity across soft tissue, cardiac, ocular, dermal, and neurological models.1,2
Tβ4 binds to monomeric G-actin, regulating actin polymerization dynamics and supporting cellular processes such as migration, proliferation, and differentiation. This actin-related function underpins many of the peptide’s observed effects on wound closure rates, angiogenesis, and extracellular matrix organization in laboratory systems.1
In animal models, Thymosin Beta-4 has been associated with:
The peptide’s combination of actin modulation, pro-angiogenic signaling, and apparent cytoprotection makes Thymosin Beta-4 a versatile research tool for studying multi-step tissue repair processes under controlled preclinical conditions.1,3,4
Thymosin Beta-4 is widely utilized in cell culture and animal models to interrogate core mechanisms of repair and regeneration. Representative areas of investigation include:
Multiple preclinical studies indicate that Tβ4 can accelerate re-epithelialization, support keratinocyte migration, and improve dermal wound architecture in both normal and impaired healing models (e.g., diabetic or aged animals).2,3 Research designs often measure time to closure, granulation tissue quality, and collagen organization as key endpoints.
In myocardial infarction and ischemia-reperfusion models, Thymosin Beta-4 has been investigated for its potential to reduce cardiomyocyte loss, enhance epicardial activation, and promote neovascularization within the infarct border zone.3,4 Researchers typically track ventricular function, infarct size, and capillary density to characterize these effects.
Endothelial and progenitor cell models are used to evaluate how Tβ4 influences angiogenic behavior, including tube formation, migration, and survival under hypoxic conditions.4 These studies help map the peptide’s role in vascular remodeling and its potential synergy with stem-cell–based strategies for tissue repair.
Thymosin Beta-4 has been examined in traumatic brain injury and stroke models for its potential to support endogenous neurogenesis, reduce secondary injury, and facilitate functional recovery.5,6 Outcome measures often include lesion volume, neuronal survival, and behavioral or motor function scores.
Important Research Notice: Nordsci Peptides provides Thymosin Beta-4 exclusively for institutional and laboratory research. Each batch is supported by Certificate of Analysis (COA) documentation including HPLC and mass spectrometry verification to confirm peptide identity and purity for research workflows.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
Each lot of Thymosin Beta-4 supplied by Nordsci Peptides is accompanied by a Certificate of Analysis summarizing:
Please refer to the COA provided with your shipment or contact customer support to obtain digital COA documentation associated with a specific lot number.
Thymosin Beta-4 should be sourced from specialized peptide suppliers that prioritize analytical verification, documented chain-of-custody, and research-only compliance. Nordsci Peptides focuses exclusively on research-grade peptide distribution, with a product catalog designed for metabolic, regenerative, and performance-related preclinical models.
Procurement Guidelines for Research Institutions
When adding Thymosin Beta-4 to a laboratory’s peptide panel, purchasing teams and principal investigators should confirm that:
IMPORTANT: Thymosin Beta-4 from Nordsci Peptides is supplied solely for in vitro and preclinical research. It is not approved for human or veterinary applications, compounding, or clinical use of any kind.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
